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Abstract
Background: Existing guidelines do not offer a quick, efficient alternative to the patient’s recollection of relevant
clinical features during anamnesis and physical examination for chronic urticaria (CU). This study aimed to identify
specific items reflecting the main characteristics of CU that should be included in a comprehensive medical history
for patients with CU. We also aimed to clarify possible eliciting factors for CU to support accurate diagnosis of the
disease.
Methods: A panel of postgraduate dermatologists conducted a literature search for relevant studies on CU using
Medline, the Cochrane database, and PubMed.
Results: We identified82 articles from which we drew a collection of items to inform development of an easy-to-
use checklist and collection of items that should be included in a correct medical history. The final version of the
checklist included42 items across two areas: essential clues for anamnesis and diagnosis of CU; and typical
symptoms/parameters or characteristics according to subtype, etiology, and laboratory findings. Items included
time of disease onset; duration, shape, size, color, and distribution of wheals; associated angioedema; atopy; and
triggering factors.
Conclusions: Our guide provides an easy-to-use tool to support clinicians to focus, orient themselves, and save
time in medical consultations for CU, allowing better diagnosis and management of this disease.
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Background
Urticaria is characterized by the development of wheals
(hives), angioedema, or both [1]. Three common features
of wheals are swelling and erythema, itching/burning
sensations, and transient nature with the skin returning
to a normal appearance within 1–24 h [2]. Angioedema
is characterized by sudden localized, pronounced ery-
thematous or skin-colored swelling of the lower dermis
and subcutis, with frequent involvement below mucous
membranes and sometimes pain rather than itching. An-
gioedema is slower to resolve than wheals, and can take
up to 72 h [1, 3].
The prevalence of CU in the general population ranges
from 0.5–5%, with the incidence of CU in Western
countries estimated at 1.4% per year [1]. In Spain, CU
ranks fourth among the allergic diseases after rhinitis,
asthma, and drug allergy [4];the prevalence of CU is
0.6%, and is significantly higher in women than men.
The average age of onset is 40 years [5]. A study in the
United Kingdom showed that the prevalence of all forms
of urticaria was 8.8% [4]. In Italy, the prevalence of
chronic spontaneous urticaria (CSU) was 0.38% in 2013,
with an incidence of 0.10–1.50 per 1000 person-years;
female patients outnumbered males in both prevalence
and incidence rates [6]. An Argentine guideline for urti-
caria and angioedema indicates 20% of the population
have urticaria at some point in their life [7]. However,
the point prevalence, cumulative prevalence, and lifetime
prevalence of chronic urticaria (CU) in Latin America
have not yet been established.
Urticaria is classified into two major types according
to duration: acute urticaria (<6 weeks) and CU (≥6 weeks)
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[2]. For clinical purposes, CU is further classified into
two subtypes: CSU and inducible urticaria (CINDU).
CSU is characterized by the spontaneous appearance of
wheals, angioedema, or both, resulting from unidentified
causes and physiopathology that is not fully understood.
Currently, the only identified aggravating factor is non-
steroidal anti-inflammatory drugs (NSAIDs). CSU also
has spontaneous remission, making it difficult to prove
cause-effect relationships.
There is a subgroup of CSU patients (40%) who has
autoantibodies against the FcεRI, the high affinity recep-
tor for IgE, that can stimulate and activate mast cells.
The presence of these autoantibodies may be clinically
important in a group of severely affected, treatment-
resistant patients, where immunomodulatory treatments
may be valuable. Patients with autoantibodies have no
distinctive diagnostic clinical features. However, they do
tend to have more severe urticaria [8].
In contrast, CINDU has known triggering stimuli, which
can be classified as symptomatic dermographism, caused
by cold, delayed pressure, sunlight, heat, vibration, cholin-
ergic, contact, or water [1]. There is often an overlap
between CSU and CINDU (e.g., a factitious component in
CSU), and there is a tendency to sub-summarize both
forms as CU [9].
We included urticarial vasculitis (UV) in this study.
UV is not a form of CU, however is necessary to exclude
it in patients with CU. In UV, the lesions are painful,
burning, and tender, with plaques lasting for more than
24 h (sometimes up to 72 h). The wheals are associated
with residual purpura or hyperpigmentation, and can
have a central dark red or brown macule signifying
underlying purpura and vasculitis. Other characteristics
of UV are swelling, residual bruising, and edema from
focused pressure; in such cases, skin biopsy would
confirm or reject the diagnosis [10–13]. A study in
Ecuador found that 10% of the population has UV [14].
This study aimed to determine a collection of items
covering the main characteristics of CU that should be
included in a comprehensive medical history to support
thorough anamnesis and physical examination. We also
evaluated possible eliciting factors of CU to aid accurate
diagnosis of the disease and obtain comprehensive infor-
mation on each patient that will then allow to select the
best approach for treatment.
It is important to emphasize that this collection of
items should not limit physical examination findings,
which can vary and include features of other forms of
urticaria; however, it provides a way to orient physicians
in thinking about CU.
Methods
For the purpose of this study, a panel of postgraduate
dermatologists conducted a literature search. Inclusion
criteria were: studies on the approach for patients with
urticaria, anamnesis, physical examination, clinical fea-
tures, characterization of lesions, and factors triggering
CU; studies in English and Spanish; and articles pub-
lished before 2016. Databases searched included Med-
line, the Cochrane database, and PubMed. Studies about
the prevalence and treatment of CU were excluded.
The criterion used to identify relevant items was spe-
cific patterns or features of lesions described in the se-
lected studies that correlated with the forms of CU. For
example, localized hives appearing after a temperature
change (cold or heat urticaria), and those induced by
pressure (e.g., delayed pressure urticaria).
These items were included in the first draft and subse-
quently, a medical history was performed. A new revi-
sion and agreement between authors was done until the
final version of the checklist was designed.
Results
In total, 82 articles were selected and used to develop a
42-item checklist for taking a comprehensive medical
history for CU. The guide and checklist are presented in
Additional files 1 and 2. Checklist items covered two
main areas:
1. Essential features for anamnesis and diagnosis of
CU.
2. Typical symptoms/parameters or characteristics
according to CU subtype, etiology, and laboratory
findings.
Checklist items included:
1. Time of disease onset
– Very rapid (less than 2 h): CINDU:
dermographism, 6–7 min; cold urticaria, 2–
5 min; heat urticaria, a few minutes to hours [15];
aquagenic urticaria, 5–10 min [16]; urticaria from
exercise, 6–25 min [17]; cholinergic urticaria, 6–
25 min [17]; vibratory angioedema, 2–30 min;
and solar urticaria, 2–15 min [18].
– More than 2 h: Pressure urticaria, 4–8 h [19].
2. Duration of wheals
– Less than 24 h: CINDU (<2 h), which includes
dermographism (<30 min), aquagenic urticaria
(<60 min) [16], solar urticaria (<60 min) [18],
contact urticaria (2 h), and the majority of
urticaria subtypes.
– More than 24 h: Pressure urticaria(24 h) [19];
UV(often 2–3 days, and may leave bruising) [2,
20].
3. Shape, size, color, and distribution of wheals
– Size 1–5 mm: cholinergic urticaria, heat urticaria,
solar urticaria [21]. Greater than 5 mm: cold
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urticaria, chronic autoimmune urticaria.
Coalescent: pressure urticaria [22]. Heat urticaria,
solar and cold urticaria can come with small or
large wheals depending on the area of skin that is
exposed to the trigger.
– Shape: UV courses with petechiae/ecchymosis,
livedo reticularis/Raynaud’s phenomenon, and
sometimes blisters [23, 24].
– Color: erythematous (most hives); yellowish to
red brown, urticaria pigmentosa (mastocytosis)
[25]; erythematous with whitish halo, aquagenic
urticaria [16] and CSU; purpuric, UV [23].
– Distribution: CINDU from pressure, solar and
dermographic stimuli share a localized
distribution [17]. Pressure and dermographic
urticaria involve feet, hands, buttocks, and
shoulders; cold, heat, and solar urticaria affect
exposed areas; UV mostly affects the lower limbs
[2, 17, 19]. Otherwise, cholinergic urticaria can be
generalized (with a predilection for the trunk and
upper extremities).Cold urticaria can be
generalized if the entire skin is exposed to cold.
4. Onset symptoms
Dermographic urticaria can sometimes begin with
erythema and hives [26]. Cold urticaria presents
with erythema, edema, and pruritus at onset.
Pruritus, edema, and burning in pressure urticaria,
cold urticaria and UV [17, 24].
5. Associated angioedema
Through inherited deficiency of C1 esterase
inhibitor, maybe localized or generalized; triggered
by physical trauma, stress, drugs, or food;
gastrointestinal compromise (angioedema)
[27]. Typically, hereditary angioedema is not
associated with urticarial skin lesions.
6. Associated subjective symptoms of lesions
Itching, pain, and burning in pressure urticaria and
UV. Burning in UV [23] and cold urticaria [28].
7. Family and personal history regarding urticaria and
atopy
Some reports mention a marked prevalence of atopy
in CSU and CINDU, with the most common cases
being allergic asthma, rhinitis, and contact allergy
[29, 30].
8. Provoking factors for wheals
– Physical stimuli in CINDU: Cold (cold urticaria);
heat (heat urticaria); sunlight (solar
urticaria); water (aquagenic urticaria); pressure
(pressure urticaria), machines that transmit
vibration such as mixers or pruners (vibratory
urticaria); rubbing (dermographic urticaria);
physical exercise (cholinergic urticaria); and stress
(CSU). Surgical implantations and events during
surgery: implants, intrauterine contraceptive
devices [31], surgical clips, metal prostheses [32],
orthopedic implants [33], femoral prosthesis (e.g.,
Smith-Petersen Vitallium nail) [34]
– Infections: The association between infections
and urticaria can be considered more direct in
cases where urticaria disappears after treatment
of infection. The role of infections in chronic
urticaria as a causative agent in CU is still
controversial however in a systematic review has
been reported as an etiologic in approximately 6%
of cases [35]. Identified etiologic agents are:
bacteria (Streptococcus spp., Staphylococcus spp.,
Yersinia, Helicobacter pylori, Treponema
pallidum); viruses(hepatitis B and C,
cytomegalovirus, Epstein-Barr virus, norovirus);
parasites,(Blastocystishominis, Giardia lamblia
[adults], Toxocara canis [children], Strongyloides
stercoralis, Trichinella, Trichomonas vaginalis,
Anisakis, Enterobius vermicularis [pinworms])
[36]; and fungi (candidiasis, dermatophytosis)
[35].
– Contact: latex, nickel, animals, steam cooking,
perfumes, and pollens (rare cases reported) [1, 9].
– Drugs: NSAIDs can trigger CSU and angioedema
[3, 37].
9. Diurnal and nocturnal variation
Pruritus of urticaria in children and adults displays
extensive temporal variability. It is worse nocturnally
in chronic urticaria, often disturbing sleep, and is
bothersome to a lesser extent upon awakening [38].
Recent findings suggest the circadian clock is an
important regulatory component of local and
systemic allergic reactions [39, 40].
10. Psychosomatic and psychiatric diseases
Mainly anxiety and depression [41]. Patients with
CU have higher scores in both the Beck Depression
Inventory and the Beck Anxiety Inventory [42]. In
addition, a reduction of productivity may be caused
by sleep interference [43].
11. Gastric/intestinal problems
Patients with symptoms of dyspepsia should
undergo to a routine test to screen for H. pylori.
Although H. pylori eradication has no discernible
effects on CSU beyond that of standard CSU
therapy, H. pylori eradication should only be
initiated in accordance with currently accepted
indications in its treatment guidelines [44].
12. Relationship to the menstrual cycle
Menstrual Cycle is an aggravating factor in CSU. A
rare form of urticaria is related to the menstrual
cycle, appearing 7–10 days before menstruation [45,
46]. There are also pruritic urticarial papules and
plaques of pregnancy occurring postpartum, related
to skin stretching in the third trimester of pregnancy
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and characterized by the abrupt eruption of
intensively pruritic papules (1–2 mm) that can
coalesce to form plaques. These lesions spread over
the distended abdomen [47].
13. Smoking habits (especially use of perfumed tobacco
products or cannabis)
Agents such as tobacco may aggravate CU [48].
14.Type of work
Particularly vulnerable populations include
healthcare workers, hairdressers, and food handlers
[49]. Other vulnerable occupations are agricultural,
dairy, and veterinary workers [50]. CU has also been
reported during exposure to cyclic anhydrides
(plumbers, packers, and painters) [51].
15. Previous diagnostic procedures/results
Routine screening for malignancies in the diagnosis
of underlying causes for urticaria is not suggested;
however, if underlying causes are suspected, further
research is necessary [1]. A prevalence of at least
one anti-thyroid antibody has been described in
20% of patients with CSU, and is associated with
more severe and prolonged urticaria progression.
Urticaria has also been described as an initial
finding for a patient with a carcinoid tumor [52].
Physicians should consider the possibility of
neuroendocrine malignancies (specifically type
I carcinoid tumors) when evaluating patients
with rare urticaria presentations [52].
Discussion
Physicians must promptly detect problems to success-
fully weigh the importance of findings in clinical settings
and react appropriately. A thorough history and physical
examination to identify all possible eliciting factors and
causes of CU are important for diagnosis [53].
International guidelines for the diagnosis and manage-
ment of CU are available, with most recommending diag-
nostic procedures when a doctor has a clinical suspicion
of CU. These existing guidelines provide example recom-
mendations to differentiate between CSU, CINDU, and
other differential diagnoses, and to measure disease activ-
ity and impact. However, they do not offer a quick or
efficient alternative to a patient’s recollection of relevant
clinical features during anamnesis and physical examin-
ation. Most existing guidelines are general, and not par-
ticularly useful for clinical practice and informing oriented
history-taking in the first doctor-patient meeting.
Physicians need an easy-to-use tool that helps them to
quickly and easily diagnose this pathology. Therefore, this
checklist has general and specific parameters ordered
according to the sequence of a comprehensive clinical
history. In addition, the checklist is able to be used by
physicians independent of specialty (e.g., emergency
rooms, primary care, internal medicine, and allergy and
dermatology departments) without causing confusion as
to the various differential diagnoses. The checklist will
also contribute to the proper management of patients with
CU from the start of clinical occurrence, achieving better
control of the disease and reducing its social and eco-
nomic impact. Delay in diagnosis statistically significantly
increases severity, correspondingly increasing healthcare
costs (specifically outpatient visit costs) and wages lost
because of absences from work [8].
We developed an easy-to-use tool to support the early
correct diagnosis and management of CU and facilitate
healthcare providers/physicians’ diagnostic workup, clin-
ical approach and allow to select the best approach for
treatment in patients with CU.
To our knowledge, this is the first checklist available for
diagnostic workup and management of patients with CU
since 2010. In 2014, a clinical history of CU was published
that provided a model for questions directed to patients
suspected of this pathology [14]. However, that model did
not cover specific features important in the clinical diag-
nosis of CU subtypes (such as color, characteristics of
lesions, distribution of wheals, associated symptoms, and
other possible etiologic agents), and did not include sup-
porting evidence for each question as detailed in the
present checklist [3, 14, 54].
In the last 30 years, attention has been focused on new
ways to understand and manage urticaria. This includes
the recent addition of novel drugs to the therapeutic ar-
senal, updating of clinical practice guidelines, and publi-
cation of pathophysiologic insights. Three decades ago,
it would not have been possible to develop easy-to-use
clinical guidance such as that developed here.
There are some limitations to our checklist. First, in
CU, etiology is a major challenge for physicians because
the frequency and relevance of infectious diseases vary
among patient groups and geographical regions. We rec-
ommend further research to develop specific tools
adapted to the context of each country. In addition, our
study does not provide a “real-world” evaluation of the
checklist or its impact. The present study did not intend
to validate the role of our checklist in the medical
history; consequently, face validity and reliability need to
be established in a future study. Future studies should
also evaluate the usefulness of this checklist. The initial
version of the checklist was in Spanish, and it is also ne-
cessary to explore the usefulness of the checklist in other
languages. A final limitation is that the checklist may be
considered too long for some physicians. However, the
length of the checklist is justified by relevant parameters
that cannot be omitted from a clinical history for a pa-
tient with CU.
A strength of our study was that we performed an
extended literature search to identify semiological and
interrogatory characteristics that permitted our checklist
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to include all items necessary to collect comprehensive
information from patients with CU. In a previous study,
we found that knowledge of guideline recommendations
among physicians who treat patients with urticaria in
Ecuador was low [55]. The diagnostic workup and treat-
ment of patients with CU was largely inconsistent with
guideline recommendations in actual practice settings.
The development of our checklist will help physicians to
collect important patient medical data and facilitate
workup and diagnosis. In future, it may also support col-
laboration in increasing knowledge about CU and its ac-
tual frequency, as data about the prevalence of CU are
not available in Latin America [7].
Conclusions
Urticaria consultations can be frustrating for both pa-
tients and physicians, because lesions may persist, fac-
tors that elicit urticaria are confusing, and there is a risk
of misdiagnosis. The easy-to-use checklist developed in
the present study should be adapted to the context of
each country to reflect the most common CU etiology.
Finally, this checklist will help focus and orient physi-
cians, and save time in medical consultations, allowing
physicians to perform better diagnosis and management
of this disease.
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